In prostate cancer, fluorescence combined with radionuclide imaging or biomarker PSMA aims to improve the accuracy of identifying lymph node metastases, avoiding the omission of potentially metastatic lymph nodes, and reducing complications associated with ePLND. Here, FOLH1 is linked to prostate cancer.